Biotech Co. Revance Faces Suit After Tender Offer Weakens

By Emilie Ruscoe · January 6, 2025, 7:42 PM EST

Biotechnology company Revance Therapeutics Inc. and two of its executives face a proposed investor class action alleging the company hurt investors after the value of a take-private tender offer was negotiated...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Matney v. Revance Therapeutics, Inc. et al

Case Number

Court

Tennessee Middle

Nature of Suit

Securities/Commodities

Date Filed

January 03, 2025

Recent Articles By Emilie

January 07, 2025
Obesity Drug Maker Faces Investor Suit Over IPO Disclosures
January 02, 2025
Eye Drug Study Blindsided Pharma Co. Investors, Suit Says
December 16, 2024
Ginkgo Bioworks Investors Get Final OK Of $17.8M Settlement
December 13, 2024
Pharma Co. Brass Face Investor Suit Over Drug Trial Probe
December 06, 2024
Two Firms To Rep CVS Investors In Benefit Unit Losses Suit
November 05, 2024
Bright Health Beats Investor Suit Over COVID-19 Costs
October 30, 2024
LA Times Owner Faces Investor Suit Over Drug Co.'s Woes
October 28, 2024
Moderna Brass Hit With Investor Suit Over RSV Shot Claims
October 22, 2024
Pharma Co. Verrica Faces Derivative Suit Over FDA Inspection
October 16, 2024
Pharma Co. Contractor Settles SEC Insider Trading Claim